Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line
摘要:
Indolizine and annulated indolizine derivatives incorporating a cyclopropylcarbonyl group were synthesized in a one pot procedure by the tanden reactions of [3 + 2] cycloaddition of the corresponding N-ylide with electron deficient alkene. Seventeen indolizine derivatives were reported for the first time. All the compounds were examined for their antiproliferative activity against the human hepatocellular liver carcinoma (Hep-G2) cell line by MTT method. Among the compounds tested, 5a, 5d, 5g and 5j showed the most favorable activities with IC50 values of 0.39, 0.48, 0.29 and 0.20 mu g/mL. Especially, compound 5j displayed potent antiproliferative activities with IC50 value of 0.20 mu g/mL, and showed significant EGFR kinase inhibitory activity with IC50 value of 0.085 mu M. Docking simulations of 5j were carried out to illustrate the binding mode of the molecular into the EGFR active site. (C) 2010 Elsevier Masson SAS. All rights reserved.
Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line
摘要:
Indolizine and annulated indolizine derivatives incorporating a cyclopropylcarbonyl group were synthesized in a one pot procedure by the tanden reactions of [3 + 2] cycloaddition of the corresponding N-ylide with electron deficient alkene. Seventeen indolizine derivatives were reported for the first time. All the compounds were examined for their antiproliferative activity against the human hepatocellular liver carcinoma (Hep-G2) cell line by MTT method. Among the compounds tested, 5a, 5d, 5g and 5j showed the most favorable activities with IC50 values of 0.39, 0.48, 0.29 and 0.20 mu g/mL. Especially, compound 5j displayed potent antiproliferative activities with IC50 value of 0.20 mu g/mL, and showed significant EGFR kinase inhibitory activity with IC50 value of 0.085 mu M. Docking simulations of 5j were carried out to illustrate the binding mode of the molecular into the EGFR active site. (C) 2010 Elsevier Masson SAS. All rights reserved.
A formal [3 + 2] annulation reaction of propargyl sulfonium compounds and <i>N</i>-ylides: access to pyrrolo[2,1-<i>a</i>]quinolines, pyrrolo[2,1-<i>a</i>]phthalazines and indolizines
作者:Jing Zheng、Xiaojie He、Hong Xu、Hua Liu、Weiran Yang
DOI:10.1039/d0ob01739f
日期:——
A sequential [3 + 2] annulation of prop-2-ynylsulfonium salt and N-ylides was developed, leading to the formation of a series of pyrrolo[2,1-a]quinolines, pyrrolo[2,1-a]phthalazines and indolizines. The protocol featured the simultaneous one-pot formation of three new C–C bonds in moderate yields under mild conditions. In this reaction, the prop-2-ynylsulfonium salts acted as the C2 synthons and sulfide
开发了丙-2-炔基锍盐和N-叶立德的顺序[3 + 2]环化,导致形成一系列吡咯并[2,1 - a ]喹啉、吡咯并[2,1 - a ]酞嗪和中氮茚。该协议的特点是在温和条件下以中等收益率同时一锅形成三个新的 C-C 键。在该反应中,prop-2-ynyl 锍盐充当 C2 合成子,硫化物充当离去基团。所得产物可作为合成多种化合物的有用前体。
Synthesis and antiproliferative activity of indolizine derivatives incorporating a cyclopropylcarbonyl group against Hep-G2 cancer cell line
Indolizine and annulated indolizine derivatives incorporating a cyclopropylcarbonyl group were synthesized in a one pot procedure by the tanden reactions of [3 + 2] cycloaddition of the corresponding N-ylide with electron deficient alkene. Seventeen indolizine derivatives were reported for the first time. All the compounds were examined for their antiproliferative activity against the human hepatocellular liver carcinoma (Hep-G2) cell line by MTT method. Among the compounds tested, 5a, 5d, 5g and 5j showed the most favorable activities with IC50 values of 0.39, 0.48, 0.29 and 0.20 mu g/mL. Especially, compound 5j displayed potent antiproliferative activities with IC50 value of 0.20 mu g/mL, and showed significant EGFR kinase inhibitory activity with IC50 value of 0.085 mu M. Docking simulations of 5j were carried out to illustrate the binding mode of the molecular into the EGFR active site. (C) 2010 Elsevier Masson SAS. All rights reserved.